SeaStar Medical Holding Corporation (ICU) Stock Score, Valuation & Financial Research

SeaStar Medical Holding Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ICU

SeaStar Medical Holding Corporation does not currently have a complete Wall Street Score. The stored market price is USD 3.19. These figures are a research snapshot, not a buy or sell recommendation.

What SeaStar Medical Holding Corporation does

SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

SeaStar Medical is a commercial-stage medical technology company that generates revenue primarily through the sale of its proprietary Selective Cytopheretic Device (SCD) therapy, marketed as QUELIMMUNE. The company sells these devices to hospitals for use in treating critically ill patients experiencing acute kidney injury and other hyperinflammatory conditions, relying on clinical adoption and hospital procurement processes.

Products and services

  • The company's primary product is the Selective Cytopheretic Device (SCD), a cell-directed therapy designed to selectively target and modulate activated neutrophils and monocytes to reduce systemic inflammation in critically ill patients.

Brands and product families

  • QUELIMMUNE — The company's primary commercialized Selective Cytopheretic Device (SCD) therapy. Source

Customer types

Hospitals.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production and assembly of its medical devices. Source

Business strengths to evaluate

  • Breakthrough Device Designation for SCD therapy Source
  • Experienced senior management and Board with expertise in regulatory and medical affairs Source

Business risks and research considerations

  • History of operating losses and potential need for additional capital Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ICU financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.19
Market capitalization:
9.05M (currency not supplied)
Revenue:
USD 1.71M
Net income:
USD -13.63M
Free cash flow:
USD -13.6M
Cash:
USD 6.96M
Total debt:
USD 525K
EPS:
USD -3.91

What stands out

  • Reported year-over-year revenue growth is +38.8%.
  • Free cash flow is USD -13.6M, negative for the stored period.
  • The balance sheet shows USD 6.96M of cash versus USD 525K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -793.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -795.5% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 6.43M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ICU

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can ICU sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • How long can ICU fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ICU likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ICU to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ICU's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research ICU

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.